Organization
Zymeworks BC
1 clinical trial
1 abstract
Clinical trial
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing CancersStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Abstract
Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2‑amplified biliary tract cancer (BTC).Org: Zymeworks BC, BeiGene Ltd.,